CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

• DOI: 10.1126/science.1198443
• Publication Date: 2011-03-24T20:28:09Z
• Authors: Gregory L. Beatty; Elena G. Chiorean; Matthew P. Fishman; Babak Saboury; Ursina R. Teitelbaum; Weijing Sun; Richard D. Huhn; Wenru Song; Dongguang Li; Leslie L. Sharp; Drew A. Torigian; Peter J. O’Dwyer; Robert H. Vonderh...
• Keywords: Adult; Male; Macrophages; Antibodies, Monoclonal; Antineoplastic Agents; Macrophage Activation; Middle Aged; Antibodies, Monoclonal, Humanized; Deoxycytidine; Disease-Free Survival; 3. Good health; Disease Models, Animal; Mice; Antineoplastic Combined Chemotherapy Protocols; Animals; Humans; Female; CD40 Antigens; Immunologic Surveillance; Aged; Carcinoma, Pancreatic Ductal

CD40 immunotherapy shows efficacy in treating pancreatic cancer in mice and humans by eliciting antitumor immunity.